Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Tioma Therapeutics

Request full access

Venture-stage biopharmaceutical company

St. Louis, United StatesFounded 2006Biotech & Life Sciences

About Tioma Therapeutics

Tioma Therapeutics, Inc., operating as a venture-stage biopharmaceutical company, focuses on the immuno-oncology sector. The company directs its efforts towards developing and discovering anti-CD47 antibodies for treating both solid and hematologic cancers. Founded in 2006 as Vasculox, Inc., the firm underwent a rebranding to Tioma Therapeutics in 2016, and later became known as Arch Oncology. The company was established by scientific founder William A. Frazier, a professor at Washington University School of Medicine who was pivotal in discovering that CD47 is a receptor for thrombospondin-1. This foundational research underpins the company's entire therapeutic platform.

The company’s core business revolves around developing a portfolio of therapeutic antibodies that target CD47 signaling pathways. The primary product candidates are immune checkpoint inhibitors designed to block the CD47 protein, which cancer cells use to send a "don't eat me" signal to the immune system. By inhibiting this signal, Tioma's antibodies enable the innate and adaptive immune systems to recognize and attack tumor cells. This approach is being evaluated for various applications, including the treatment of cancer, pulmonary hypertension, and preventing complications from solid organ transplants. The business model is centered on advancing its antibody portfolio through clinical trials to establish proof-of-concept, with the ultimate goal of commercialization or strategic partnerships within the pharmaceutical industry.

A significant milestone in the company's history was securing an $86 million Series A financing in August 2016. This round was co-led by prominent venture capital firms, including RiverVest Venture Partners, Novo Ventures, Roche Venture Fund, and S.R. One, the corporate venture arm of GlaxoSmithKline. The funding was allocated to advance the lead drug candidate through human clinical trials and further develop the antibody portfolio. Operationally, the company maintains its research laboratories in St. Louis, Missouri, while its corporate headquarters are located in the San Francisco Bay Area.

Source: Dealroom company data

At a glance

Status
Operational
Employees
1
Open positions
None listed
Dealroom signal
24.3/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Immune System, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing Apr 2021 $105M $420M Adage Capital · Broadfin · RiverVest Venture Partners · Point72 ↗
SERIES BOther financing Mar 2019 $50M $200M Cultivation Capital · RiverVest Venture Partners · Roche Venture Fund ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Tioma Therapeutics website traffic

Latest recorded traffic for Tioma Therapeutics is 110 monthly website visits. Tioma Therapeutics's team grew 0% over the past year.

Latest monthly visits110 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Tioma Therapeutics in the St. Louis ecosystem

Live from Dealroom

The Tioma Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Cultivation Capital

Series A4 investors entered at this stage

  • SR One
  • RiverVest Venture Partners
  • Roche Venture Fund
  • Novo Ventures

Series B and later3 investors entered at this stage

  • Adage Capital
  • Broadfin
  • Point72
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · St. Louis HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Tioma Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Tioma Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.